ArticleCureus2025
Hypogonadal Rescue in Post-orgasmic Illness Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-orgasmic Illness Syndrome (POIS) is a debilitating and poorly understood condition characterized by multi-system symptoms following ejaculation. We report a hormonally responsive POIS phenotype treated with clomiphene citrate and niacinamide. A 36-year-old Middle Eastern man (BMI 24.5) fulfilling all six Waldinger diagnostic criteria for POIS underwent baseline endocrine profiling and symptom assessment, including serum testosterone, estradiol, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). He was treated with clomiphene citrate 50 mg daily and niacinamide 500 mg daily for three months, with monthly safety monitoring. Pretreatment testosterone was 10.7 nmol/L (normal 8.6-29.0), estradiol 114 pmol/L (41-159), and total symptom score 62/90. After three months, testosterone normalized to 41.9 nmol/L and estradiol rose to 229 pmol/L, with a 26% reduction in total symptom score and a decrease in episode duration from 12 to nine days. No adverse events or laboratory abnormalities occurred. Targeted endocrine modulation with clomiphene and niacinamide produced a clinically meaningful reduction in symptom burden and episode duration in this POIS case, supporting routine hormonal assessment and personalized therapy. Prospective, controlled trials employing validated outcome measures are warranted to establish efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.